Celebrating 25 years Est 1999-2024
*Across 3 years $2158.56 only $1079.28
TORONTO, May 7 /PRNewswire-FirstCall/ -- The Pediatric Infectious Diseases Society (PIDS), supported by grants from MedImmune, Inc...
GAITHERSBURG, Md., May 2 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) today announced that, in connection with the previously...
GAITHERSBURG, Md., May 2 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) today announced that seven abstracts will be presented at the...
GAITHERSBURG, Md., April 30 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that a 15-percent increase in total revenues...
- New Compound Targeting Receptor Tyrosine Kinase EphA2 Shows Tumor Destruction at Low Dose Levels in Preclinical Models - GAITHERSBURG, Md. and...
- Preclinical Data Support Rationale for Targeting Pro-Inflammatory Protein - GAITHERSBURG, Md., April 18 /PRNewswire-FirstCall/ -- MedImmune...
GAITHERSBURG, Md. and CARLSBAD, Calif., April 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (NASDAQ:MITI) and MedImmune, Inc. (NASDAQ:MEDI) today...
New York, April 16 /PRNewswire/ -- Several weeks ago, as a large shareholder of MedImmune, Inc. (NASDAQ:MEDI), Carl Icahn informed the company...
GAITHERSBURG, Md., April 12 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) today announced that its board of directors has authorized...
Company Invites Investors to Participate in First-Quarter 2007 Earnings Conference Call on May 3, 2007 GAITHERSBURG, Md., April 9...
-- Experts Recognized for their Expanded Strategic Contributions in Driving Pipeline Progress GAITHERSBURG, Md., April 2 /PRNewswire-FirstCall/...
GAITHERSBURG, Md., April 2 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that Robert H. Hotz has been appointed to its...
CHICAGO, March 30 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for key stocks. Seven Summits Strategic Investments...
GAITHERSBURG, Md., March 29 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that it has licensed its proprietary reverse...
GAITHERSBURG, Md., March 23 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) today announced that it has initiated a Phase 1 trial with...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.